Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

Tsao Anne S.; Miao Jieling; Wistuba Ignacio I.; Vogelzang Nicholas J.; Heymach John V.; Fossella Frank V.; Lu Charles; Velasco Mario R.; Box-Noriega Brandy; Hueftle James G.; Gadgeel Shirish; Redman Mary W.; Gandara David R.; Kelly Karen

首页> 外文期刊>Journal of Clinical Oncology >Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

【24h】

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

机译：Cediranib的II期试验与顺铂和化疗 - 幼稚患者中的顺铂和聚氯乙烯联合，患有不可切除的恶性胸膜间皮瘤（Swog S0905）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

PURPOSE Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demonstrated therapeutic potential in a prior phase I trial. We evaluated a phase II trial for efficacy.

机译：目的抗血管生成剂联合化疗在治疗不可切除的恶性胸膜间皮瘤（MPM）中具有功效。 Cediranib（Astrazeneca，Cheshire，United Kingdom），血管内皮生长因子受体和血小板衍生的生长因子受体抑制剂，在先前的I期试验中显示了治疗潜力。我们评估了II期试验的疗效。

著录项

来源
《Journal of Clinical Oncology》 |2019年第28期|共13页
作者
Tsao Anne S.; Miao Jieling; Wistuba Ignacio I.; Vogelzang Nicholas J.; Heymach John V.; Fossella Frank V.; Lu Charles; Velasco Mario R.; Box-Noriega Brandy; Hueftle James G.; Gadgeel Shirish; Redman Mary W.; Gandara David R.; Kelly Karen;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

SWOG Stat Ctr Seattle WA USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

US Oncol Comprehens Canc Ctr Nevada Las Vegas NV USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Canc Care Specialists Illinois Decatur IL USA;

Kaiser Permanente Fresno CA USA;

Montana Canc Consortium Billings MT USA;

Univ Michigan Ann Arbor MI 48109 USA;

SWOG Stat Ctr Seattle WA USA;

Univ Calif Davis Ctr Canc Sacramento CA 95817 USA;

Univ Calif Davis Ctr Canc Sacramento CA 95817 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905) [J] . Tsao Anne S., Miao Jieling, Wistuba Ignacio I., Journal of Clinical Oncology . 2019,第28期

机译：Cediranib的II期试验与顺铂和化疗 - 幼稚患者中的顺铂和聚氯乙烯联合，患有不可切除的恶性胸膜间皮瘤（Swog S0905）
2. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial [J] . Giorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, The lancet. Respiratory medicine. . 2019,第7期

机译：Nintedanib与Pemetryexed和Cisplatin联合用于化疗 - 天真患者的晚期恶性胸膜间皮瘤（Lume-Meso）：双盲，随机，安慰剂控制第3阶段试验
3. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol [J] . Nobukazu Fujimoto, Keisuke Aoe, Toshiyuki Kozuki, Clinical lung cancer . 2018,第5期

机译：二铂，磷酸盐蛋白化疗的第一线组合化疗的II期试验，用于不可切除的恶性胸腔间皮瘤：研究方案
4. Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients. [C] . Serge Mordon, Camille Munck, Ecaterina Surmei-Pintilie, International Photodynamic Association World Congress . 2019

机译：可行性试验评估腹膜内光动力学治疗与胸膜切除术/凝固患者患者在恶性胸膜间皮瘤患者中相结合。
5. Regulatory T cell blockade combined with pemetrexed in malignant pleural mesothelioma [D] . Anraku, Masaki. 2008

机译：调节性T细胞阻滞联合培美曲塞治疗恶性胸膜间皮瘤
6. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905) [O] . Anne S. Tsao, Jieling Miao, Ignacio I. Wistuba, -1

机译：Cediranib联合顺铂和培美曲塞的II期试验在未接受化疗的未切除恶性胸膜间皮瘤患者中的治疗（SWOG S0905）
7. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905) [O] . Anne S. Tsao, Jieling Miao, Ignacio I. Wistuba, 2019

机译：Cediranib的II期试验与顺铂和聚普拉特在化疗 - 天真患者中与不可切除的恶性胸膜间皮瘤患者（SWOG S0905）的组合

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

摘要

著录项

相似文献

相关主题

期刊订阅